CLEC4A/DCIR hFc Chimera, Mouse
CLEC4A/DCIR HFc Chimera, Mouse

The purity of CLEC4A/DCIR hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

CLEC4A/DCIR HFc Chimera, Mouse

CLEC4A/DCIR hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC4A/DCIR hFc Chimera, Mouse

Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
Z06064
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
CLEC4A/DCIR (Gln70-Leu238)_x000D_
Accession # Q9QZ15		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 46.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • CLEC4A/DCIR HFc Chimera, Mouse
    • CLEC4A/DCIR HFc Chimera, Mouse

    The purity of CLEC4A/DCIR hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

  • CLEC4A/DCIR HFc Chimera, Mouse
    • CLEC4A/DCIR HFc Chimera, Mouse

    CLEC4A/DCIR hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
Synonyms CD367; Clec4a2; CLECSF6; DCIR; DDB27; HDCGC13P; LLIR; CLEC4A; DCIRLLIR

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.